Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Alzheimer's Disease

Free Subscription Articles published in Neurology Retrieve available abstracts of 301 articles: HTML format

Single Articles

October 2026
1. PARANHOS T, Katsumi Y, Brickhouse MJ, Eloyan A, et al
   EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease: An MRI-Based Prognostic Biomarker.
   Neurology. 2026;107:e218519.
   PubMed     Abstract available
   
   
   September 2026
2. GONZALEZ-GOMEZ R, Tagliazuchi E, Campo CG, Medel V, et al
   Lesion-Level Subtypes of White Matter Hyperintensity Evolution Beyond Spatial Location.
   Neurology. 2026;107:e218472.
   PubMed     Abstract available
   
   
   
3. WAGEMANN O, Nuebling GS, Sandkuhler K, Wlasich E, et al
   Longitudinal Dynamics of the Blood Proteome Within the Alzheimer Spectrum in Down Syndrome.
   Neurology. 2026;107:e218494.
   PubMed     Abstract available
   
   
   
4. SARKIS RA, Yang HS, Liu L, Lam AD, et al
   Association Between Alzheimer Pathology, Sleep, and Cognition in Patients With Late-Onset Unexplained Epilepsy.
   Neurology. 2026;107:e218476.
   PubMed     Abstract available
   
   
   
5. MOHAMED MI, Sameh R, Farghaly D, Ashraf B, et al
   Autoimmune Neurologic Disorders and the Risk of Alzheimer, Vascular, and Other Dementias: A Comprehensive Systematic Review and Meta-Analysis (P2-13.006).
   Neurology. 2026;107:e218536.
   PubMed    
   
   
   
6. SHIR D, Corriveau-Lecavalier N, Jones DT, Ramanan VK, et al
   Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes.
   Neurology. 2026;107:e218347.
   PubMed     Abstract available
   
   
   
7. PRODAN CI, Yabluchanskiy A
   The Challenge of Atypical Alzheimer Disease Phenotypes.
   Neurology. 2026;107:e218533.
   PubMed    
   
   
   
8. SALEMME S
   Menopausal Hormone Therapy and Alzheimer Disease: When, Which, and for Whom?
   Neurology. 2026;107:e218503.
   PubMed    
   
   
   
9. BRUNO J, Shaw JS, Hosseini SMH
   Association Between Menopausal Hormone Therapy and Alzheimer Disease Neuropathology.
   Neurology. 2026;107:e218413.
   PubMed     Abstract available
   
   
   
10. HAZAN J, Salemme S, Liu KY, Howard R, et al
    Blood-Based Biomarkers for Alzheimer Disease in Primary Care: The Gap Between Biology and Clinical Utility.
    Neurology. 2026;107:e218403.
    PubMed     Abstract available
    
    
    August 2026
11. LI C, Fu M, Berg K, Wallach J, et al
    Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025: A Systematic Review.
    Neurology. 2026;107:e218373.
    PubMed     Abstract available
    
    
    
12. TURNER RS
    Clinical Trial Outcomes in the Alzheimer's Disease Spectrum: What Should We Measure?
    Neurology. 2026;107:e218468.
    PubMed    
    
    
    
13. ZHENG J, Lip GYH, Zhang Z, Lee SWR, et al
    Association of Sugar Restriction in Utero Through Age 2 Years on Dementia Risk Later in Life.
    Neurology. 2026;107:e218313.
    PubMed     Abstract available
    
    
    
14. CASARINI A, Ballerini A, Maramotti R, Tondelli M, et al
    Cognitive and Biomarker Signatures of Late-Onset Temporal Lobe Epilepsy: Toward Non-Alzheimer Neurodegenerative Mechanisms.
    Neurology. 2026;107:e218356.
    PubMed     Abstract available
    
    
    
15. KROPP E, Varkanitsa M, Stein TD, Turk K, et al
    Diagnostic Accuracy of the Boston Criteria v2.0 in Memory Clinic Patients: An MRI-Neuropathology Validation Study.
    Neurology. 2026;107:e218314.
    PubMed     Abstract available
    
    
    
16. KIVISILD A, Aaltonen M, Aho K, Heikkinen SV, et al
    Long-Term Income and Productivity Losses in Individuals With Early-Onset Dementia: Evidence From 15 Years Preceding the Diagnosis.
    Neurology. 2026;107:e218268.
    PubMed     Abstract available
    
    
    
17. GRILL JD, Graff-Radford J
    The Promise and Peril of Alzheimer Disease Prevention.
    Neurology. 2026;107:e218348.
    PubMed     Abstract available
    
    
    
18. PAEZ A, Pinol-Ripoll G, Carnes-Vendrell A, Dakterzada F, et al
    Orexin, Sleep, and Cognition in Alzheimer Disease: Non-REM Oscillatory Activity and Neural Resilience.
    Neurology. 2026;107:e218307.
    PubMed     Abstract available
    
    
    
19. BELLOMO G, Gaetani L
    Plasma P-Tau217: A Powerful Alzheimer Disease Biomarker in the Right Clinical Context.
    Neurology. 2026;107:e214821.
    PubMed    
    
    
    
20. COYSH T, Laban R, Veleva E, Heslegrave AJ, et al
    Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases.
    Neurology. 2026;107:e214712.
    PubMed     Abstract available
    
    
    
21. CHEN Y, Chen A, Power MC, Grodstein F, et al
    Associations of Alzheimer Disease and Related Dementia Neuropathologies With Timely Diagnosis of Dementia in Healthcare Settings.
    Neurology. 2026;107:e218352.
    PubMed     Abstract available
    
    
    
22. TANG C, Yang J, Luo W, Lei X, et al
    Rapidly Progressive Alzheimer Disease and Related Dementias as a Phase Transition: Symptom Cascades and Survival Inflection.
    Neurology. 2026;107:e218350.
    PubMed     Abstract available
    
    
    July 2026
23. MORRILL VN, Pike JR, Hu J, Fornage M, et al
    Genetic Risk for Alzheimer Disease, Midlife Hypertension, and Dementia: The ARIC Neurocognitive Study.
    Neurology. 2026;107:e218280.
    PubMed     Abstract available
    
    
    
24. TING SKS, Saffari SE, Zhan SJ, Gosavi TD, et al
    Neuropathologic Correlates of Seizures in Patients With Alzheimer Disease and Dementia With Lewy Bodies.
    Neurology. 2026;107:e218277.
    PubMed     Abstract available
    
    
    
25. TORT-MERINO A, Esteller-Gauxax D, Perez-Millan A, Castellvi M, et al
    Neuropsychological Profile and Cognitive Trajectories of Patients With Biomarker Evidence of Alzheimer Disease or Dementia With Lewy bodies.
    Neurology. 2026;107:e218201.
    PubMed     Abstract available
    
    
    
26. LICHTER DG
    Neuropathogenesis of Seizures in Patients With Alzheimer Disease and Lewy Body Dementia: Is There a Difference, and Does It Matter?
    Neurology. 2026;107:e218344.
    PubMed    
    
    
    
27. KIM D, McInerney K, Dagli C, Armstrong ND, et al
    Influence of Cardiometabolic and Alzheimer Disease Genetics on Cognitive-Related Outcomes in a Diverse Population.
    Neurology. 2026;107:e218163.
    PubMed     Abstract available
    
    
    
28. CASH DM, Knopman DS
    Not Lost in Translation: Universality of Clinical-Pathobiologic Correlation in Alzheimer Disease.
    Neurology. 2026;107:e218262.
    PubMed    
    
    
    
29. WANG ZY, Xin JW, Wang MY, Chen S, et al
    Clinical Evaluation of the Revised Biological and Clinical Staging Criteria for Alzheimer Disease in China.
    Neurology. 2026;107:e218184.
    PubMed     Abstract available
    
    
    
30. GANESH A, Smith EE, Mostert J, Strijbis EM, et al
    Phase 2 Futility Trials in Alzheimer Disease and Mild Cognitive Impairment: A Cohort Analysis of the ADNI Data Set.
    Neurology. 2026;107:e218227.
    PubMed     Abstract available
    
    
    
31. CERIELLO C, Torres OH, Rubio-Guerra S, Garcia-Castro J, et al
    Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old.
    Neurology. 2026;107:e218180.
    PubMed     Abstract available
    
    
    
32. GALLAY C, Soldevila-Domenech N, Lopez-Martos D, Sanchez-Benavides G, et al
    Effect of Parity and beta-Amyloid on Cognition and Hippocampal Volume in Postmenopausal Women.
    Neurology. 2026;107:e218153.
    PubMed     Abstract available
    
    
    June 2026
33. URSO D, Giannoni-Luza S, Gnoni V, Giugno A, et al
    Incidence of Dementia With Lewy Bodies in Salento, Italy: A Population-Based Study.
    Neurology. 2026;106:e218150.
    PubMed     Abstract available
    
    
    
34. TRIEU C, Dicks E, de Leeuw D, de Wit KDM, et al
    Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired Individuals.
    Neurology. 2026;106:e218119.
    PubMed     Abstract available
    
    
    
35. ZOTCHEVA E, Strand BH, Sunde A, Deckers K, et al
    Associations of Anthropometry Measures Across 35 Years With Late-Life Plasma P-tau217 and Dementia: The HUNT Study.
    Neurology. 2026;106:e218093.
    PubMed     Abstract available
    
    
    May 2026
36. CHUNG PA, Fleming VL, Reid KJ, Plante DT, et al
    Circadian Rest-Activity Rhythms, Cognition, and Alzheimer Disease Dementia in Adults With Down Syndrome.
    Neurology. 2026;106:e214938.
    PubMed     Abstract available
    
    
    
37. FANG Y, Leng Y
    Can Targeting Circadian Rhythms Help Prevent Alzheimer Disease?: Lessons From Down Syndrome.
    Neurology. 2026;106:e218086.
    PubMed    
    
    
    
38. KNOPMAN DS
    Alzheimer Plasma Biomarkers in Mild Cognitive Impairment: Each With Distinct Etiologic and Prognostic Roles.
    Neurology. 2026;106:e218042.
    PubMed    
    
    
    
39. HAZAN J, Liu KY, Isaacs JD, Fox NC, et al
    What Does a Positive Alzheimer Disease Blood-Based Biomarker Result Mean in People With Mild Cognitive Impairment?
    Neurology. 2026;106:e214953.
    PubMed     Abstract available
    
    
    
40. PARK SY, Setiawan VW, Crimmins EM, White LR, et al
    Plant-Based Dietary Patterns and Risk of Alzheimer Disease and Related Dementias in the Multiethnic Cohort Study.
    Neurology. 2026;106:e214916.
    PubMed     Abstract available
    
    
    
41. GROOT C, Calandri IL, Bader I, Bocancea DI, et al
    Characterizing Individuals Fulfilling Clinical Criteria for Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Tertiary Memory Clinic.
    Neurology. 2026;106:e214810.
    PubMed     Abstract available
    
    
    
42. BENDER AC, Berezuk C, Pellerin KR, You JC, et al
    Association of Sleep Spindle Activity With Cognitive Decline in Early Clinical Stages of Alzheimer Disease.
    Neurology. 2026;106:e214839.
    PubMed    
    
    
    
43. CARRIGAN M, Groot C
    Can a "Youthful" Brain Moderate Vulnerability to Alzheimer Disease?
    Neurology. 2026;106:e214927.
    PubMed    
    
    
    
44. SEWELL KR, Solis-Urra P, Huang H, Karikari TK, et al
    Cognitive and Brain Reserve as Modifiers of Early Alzheimer Disease-Related Cognitive Vulnerability.
    Neurology. 2026;106:e214833.
    PubMed     Abstract available
    
    
    April 2026
45. NOGUCHI-SHINOHARA M, Ono K
    Successful Amyloid Removal by Donanemab Treatment in a Female Patient With Alzheimer Disease: A Case Report.
    Neurology. 2026;106:e214817.
    PubMed    
    
    
    
46. BUKHBINDER AS, Ling Y, Jhin L, He E, et al
    Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination.
    Neurology. 2026;106:e214782.
    PubMed     Abstract available
    
    
    
47. JUNG J
    Cognitive Reserve in Genetic Alzheimer Disease: Why the Brain's "Buffer" Matters More Than We Thought.
    Neurology. 2026;106:e214887.
    PubMed    
    
    
    
48. LLIBRE-GUERRA JJ, Lu R, Clarens MF, Liu I, et al
    Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease.
    Neurology. 2026;106:e214804.
    PubMed     Abstract available
    
    
    
49. ROSS D, Split M, Kunicki Z, Keszycki R, et al
    Neuropsychiatric Symptoms in Patients With Pathologically Confirmed Comorbid Alzheimer Disease and Frontotemporal Lobar Degeneration.
    Neurology. 2026;106:e214750.
    PubMed     Abstract available
    
    
    
50. CLARK AL, Asimakopoulos G, Valocchi E, Chanfreau-Coffinier C, et al
    Individual-Level Factors Associated With 10-Year Incidence of Alzheimer Disease and Related Dementias in the VA Million Veteran Program.
    Neurology. 2026;106:e214748.
    PubMed     Abstract available
    
    
    
51. LORENZINI L, Tranfa M, Kate MT, Braber AD, et al
    CSF Proteomic Profiles Associated With White Matter Integrity in Cognitively Normal Older Adults With and Without Amyloid Pathology.
    Neurology. 2026;106:e214675.
    PubMed     Abstract available
    
    
    March 2026
52. VILLAIN N
    Reader Response: Alzheimer Disease Is a Specific Disorder Defined by Neuropathology Detectable During Life.
    Neurology. 2026;106:e210188.
    PubMed    
    
    
    
53. VILLAIN N, Hanseeuw BJ, Planche V, Paretsky MS, et al
    Author Response: The Great Debate in Diagnosing Alzheimer Disease: More Than Just a beta Test.
    Neurology. 2026;106:e210240.
    PubMed    
    
    
    
54. GANESH A, Galetta SL
    Editors' Note: Diagnostic and Prognostic Implications of Biomarker-Based Criteria for Alzheimer Disease.
    Neurology. 2026;106:e214259.
    PubMed    
    
    
    
55. BIEGER A, Brum WS, Borelli WV, Ferrari-Souza JP, et al
    Reader Response: The Great Debate in Diagnosing Alzheimer Disease: More Than Just a beta Test.
    Neurology. 2026;106:e210159.
    PubMed    
    
    
    
56. HALL BJ, Aumont E, Hosseini SA, Fernandez Arias J, et al
    Association of Cortical Free Water With Brain Tau Tangle Load in the Alzheimer Disease Continuum.
    Neurology. 2026;106:e214606.
    PubMed     Abstract available
    
    
    
57. NELSON PT, Jicha GA
    Tau Biomarker-Based Diagnosis of Alzheimer Disease and the Anti-Abeta Therapeutic Window: Is There Overlap?
    Neurology. 2026;106:e214696.
    PubMed    
    
    
    
58. VRILLON A, Spina S, Mejia-Perez J, Lamore T, et al
    Association of [(18)F]Flortaucipir-PET and Plasma p-Tau217 With Tau Neuropathology in Alzheimer Disease and Other Neurodegenerative Disorders.
    Neurology. 2026;106:e214576.
    PubMed     Abstract available
    
    
    
59. ZAMMIT AR, Yu L, Poole VN, Kapasi A, et al
    Associations of Lifetime Cognitive Enrichment With Incident Alzheimer Disease Dementia, Cognitive Aging, and Cognitive Resilience.
    Neurology. 2026;106:e214677.
    PubMed     Abstract available
    
    
    February 2026
60. KIVISAKK P, Fatima H, Wu CY, Padmanabhan N, et al
    Postmortem Associations Between Alzheimer Disease Pathology and Plasma pTau217, GFAP, and NfL in AD and AD-Related Dementias.
    Neurology. 2026;106:e214351.
    PubMed     Abstract available
    
    
    
61. IRWIN DJ
    Blood-Based Biomarkers and the Complexity of Neuropathologic Substrates of Alzheimer Disease and Related Disorders.
    Neurology. 2026;106:e214504.
    PubMed    
    
    
    
62. RANI N, Moghekar A, Callow DD, Alm KH, et al
    Association Between Longitudinal Rate of Change in CSF Biomarkers and Subsequent Tau PET Burden in Early Braak Stages.
    Neurology. 2026;106:e214620.
    PubMed     Abstract available
    
    
    January 2026
63. DU Y, Borne Y, Samuelsson J, Glans I, et al
    High- and Low-Fat Dairy Consumption and Long-Term Risk of Dementia: Evidence From a 25-Year Prospective Cohort Study.
    Neurology. 2026;106:e214343.
    PubMed     Abstract available
    
    
    
64. ROVETA F, Pizzini FB, Natale V, Scheffler M, et al
    Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic.
    Neurology. 2026;106:e214477.
    PubMed     Abstract available
    
    
    
65. GASPARINI F, Valletta M, Vetrano DL, Beridze G, et al
    Kidney Function, Alzheimer Disease Blood Biomarkers, and Dementia Risk in Community-Dwelling Older Adults.
    Neurology. 2026;106:e214446.
    PubMed     Abstract available
    
    
    
66. FERREIRA PCL, Bellaver B, Povala G, Bauer-Negrini G, et al
    Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials.
    Neurology. 2026;106:e214441.
    PubMed     Abstract available
    
    
    
67. BENDER AC, Berezuk C, Pellerin KR, You JC, et al
    Association of Sleep Spindle Activity With Cognitive Decline in Early Clinical Stages of Alzheimer Disease.
    Neurology. 2026;106:e214459.
    PubMed     Abstract available
    
    
    
68. JUNG YH, Cho J, Lee SY, Seo HE, et al
    Impact of Cerebral Microbleeds on Tau-Associated Cognitive and Structural Decline.
    Neurology. 2026;106:e214453.
    PubMed     Abstract available
    
    
    December 2025
69. COUGHLIN DG, Jain L, Khrestian M, Bozoki AC, et al
    CSF alpha-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies: Presentation and Progression.
    Neurology. 2025;105:e214346.
    PubMed     Abstract available
    
    
    
70. FILIPPI M, Cecchetti G
    Choroid Plexus Morphology in Alzheimer Disease: Bridging Pathology and Cognition.
    Neurology. 2025;105:e214017.
    PubMed    
    
    
    
71. LIN M, Zeng Q, Zhong S, Nie S, et al
    Association Between Choroid Plexus Morphological Alterations, Alzheimer Pathologies, and Cognitive Impairment: A Longitudinal Study.
    Neurology. 2025;105:e213953.
    PubMed     Abstract available
    
    
    
72. KRELL-ROESCH J, Syrjanen JA, Hansen AL, Vemuri P, et al
    Physical and Cognitive Activities and Trajectories of AD Neuroimaging Biomarkers: Longitudinal Analysis in the Mayo Clinic Study of Aging.
    Neurology. 2025;105:e214405.
    PubMed     Abstract available
    
    
    November 2025
73. BENITO-LEON J, Benito-Rodriguez CM
    Essential Tremor Dementia: Alzheimer Disease in Disguise?
    Neurology. 2025;105:e214420.
    PubMed    
    
    
    
74. RAMOS-CEJUDO J, Beiser AS, Lu S, Tanner JA, et al
    Association of Platelet Aggregation With Markers of Alzheimer Disease Pathology in Middle-Aged Participants of the Framingham Heart Study.
    Neurology. 2025;105:e214314.
    PubMed     Abstract available
    
    
    
75. PRODAN CI, Dale GL
    Platelets and Alzheimer Disease: A Link Worth Exploring.
    Neurology. 2025;105:e214438.
    PubMed    
    
    
    
76. ROSENAU C, Neuffer J, Kohler S, Helmer C, et al
    Updated LIfestyle for BRAin health (LIBRA2) Score, Genetics, and Risk of Alzheimer Disease, Vascular Dementia, and Stroke in Older Adults.
    Neurology. 2025;105:e214312.
    PubMed     Abstract available
    
    
    
77. MOURTZI N, Charisis S, Ntanasi E, Hatzimanolis A, et al
    Longitudinal Association of a Polygenic Risk Score for Plasma T-Tau With Incident Alzheimer Dementia and Mild Cognitive Impairment.
    Neurology. 2025;105:e213904.
    PubMed     Abstract available
    
    
    
78. EDWARDS NC, Lao P, Alshikho MJ, Mazen J, et al
    Alzheimer Disease, Vascular Disease, and Blood-Brain Barrier Permeability Biomarkers in Middle-Aged Adults.
    Neurology. 2025;105:e214220.
    PubMed     Abstract available
    
    
    
79. ONG JJH, Leow YJ, Qiu B, Tanoto P, et al
    Association of Enlarged Perivascular Spaces With Early Serum and Neuroimaging Biomarkers of Alzheimer Disease Pathology.
    Neurology. 2025;105:e214339.
    PubMed    
    
    
    
80. LOPEZ-MARTOS D, Suarez-Calvet M, Mila-Aloma M, Gispert JD, et al
    Longitudinal Associations of Multimodal Core 1 Alzheimer Disease Biomarkers With Cognition in Aging and Preclinical Alzheimer Disease.
    Neurology. 2025;105:e214308.
    PubMed     Abstract available
    
    
    October 2025
81. TRUDEL L, Therriault J, Macedo AC, Servaes S, et al
    Implication for Clinical Trials From Longitudinal Tau-PET Accumulation Across Biological Alzheimer Disease Stages.
    Neurology. 2025;105:e214111.
    PubMed     Abstract available
    
    
    
82. ESTELLER-GAUXAX D, Perez Millan A, Sarto J, Puey R, et al
    alpha-Synuclein Seed Amplifications Assay in a Cohort With Cognitive Impairment: Performance and Interactions With CSF and Plasma Biomarkers.
    Neurology. 2025;105:e214040.
    PubMed     Abstract available
    
    
    
83. BOCCALINI C, Mathoux G, Hristovska I, Ribaldi F, et al
    Visual Classification of Tau-PET Detects 4 Subtypes With Different Long-Term Outcomes.
    Neurology. 2025;105:e213950.
    PubMed     Abstract available
    
    
    September 2025
84. OVEISGHARAN S, Yu L, Yang J, Agrawal S, et al
    Cortical Gray Matter Proteins Associated With Cerebral Amyloid Angiopathy in Community-Dwelling Older Adults: An Autopsy Study.
    Neurology. 2025;105:e214024.
    PubMed     Abstract available
    
    
    
85. ONG JJH, Leow YJ, Qiu B, Tanato P, et al
    Association of Enlarged Perivascular Spaces With Early Serum and Neuroimaging Biomarkers of Alzheimer Disease Pathology.
    Neurology. 2025;105:e213836.
    PubMed     Abstract available
    
    
    
86. YIM S, Park S, Lim K, Kang H, et al
    Integrating MRI Volume and Plasma p-Tau217 for Amyloid Risk Stratification in Early-Stage Alzheimer Disease.
    Neurology. 2025;105:e213954.
    PubMed     Abstract available
    
    
    
87. SCHAFFERT J, Iyengar N, Magill R, LoBue C, et al
    Clinical and Neuropsychological Profiles in People With Chronic Traumatic Encephalopathy Neuropathologic Change: Matched Case-Series Study.
    Neurology. 2025;105:e214012.
    PubMed     Abstract available
    
    
    
88. WANG X, Ye T, Zhou W, Zhang J, et al
    Association of Distinct Initial beta-Amyloid Levels With Tau Pathology Expansion Beyond the Entorhinal Cortex.
    Neurology. 2025;105:e214041.
    PubMed     Abstract available
    
    
    
89. WANG L, Xu H, Simons RL, Beach SRH, et al
    Associations of Longitudinal Changes in Blood Biomarkers of Dementia With the Proportion of Genetically Inferred African Ancestry.
    Neurology. 2025;105:e213976.
    PubMed     Abstract available
    
    
    
90. RAJAN KB, Evans DA
    Author Response: Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults.
    Neurology. 2025;105:e210185.
    PubMed    
    
    
    
91. LEWIS A, Galetta SL
    Editors' Note: Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults.
    Neurology. 2025;105:e213696.
    PubMed    
    
    
    
92. KAWADA T
    Reader Response: Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults.
    Neurology. 2025;105:e209998.
    PubMed    
    
    
    
93. KAPASI A, James BD, Yu L, Sood A, et al
    Mixed Pathologies and Cognitive Outcomes in Persons Considered for Anti-Amyloid Treatment Eligibility Assessment: A Community-Based Study.
    Neurology. 2025;105:e214004.
    PubMed     Abstract available
    
    
    
94. PETERSEN RC
    Alzheimer Disease Treatments and Co-Pathologies: But At What Age?
    Neurology. 2025;105:e214061.
    PubMed    
    
    
    August 2025
95. FUKUYAMA H
    Cerebral Small Vessel Disease and Alzheimer Disease: The Vascular Link Through MRI Diffusion.
    Neurology. 2025;105:e214052.
    PubMed    
    
    
    
96. PALPATZIS E, Akinci M, Garcia-Prat M, Blennow K, et al
    Grief and Economic Stressors by Sex, Gender, and Education: Associations With Alzheimer Disease-Related Outcomes.
    Neurology. 2025;105:e214053.
    PubMed    
    
    
    July 2025
97. TRANFA M, Oliveira TG
    Scratching Beneath the Cortex: Superficial White Matter and Alzheimer Disease.
    Neurology. 2025;105:e213830.
    PubMed    
    
    
    
98. WANG S, Zhang F, Zeng Q, Hong H, et al
    Association of Superficial White Matter Microstructure With Cortical Pathology Deposition Across Early Stages of the AD Continuum.
    Neurology. 2025;105:e213666.
    PubMed     Abstract available
    
    
    
99. BARNARD L, Botha H, Corriveau-Lecavalier N, Graff-Radford J, et al
    An FDG-PET-Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders.
    Neurology. 2025;105:e213831.
    PubMed     Abstract available
    
    
    
100. VANDERLIP CR, Stark CEL
     Time Course and Severity of Cognitive Changes as a Function of Abeta Positivity and APOE Genotype in Alzheimer Disease.
     Neurology. 2025;105:e213853.
     PubMed     Abstract available
     
     
     
101. ZIMMERMAN SC, Choi M, Jiang C, Ferguson EL, et al
     Statin Initiation and Dementia Incidence in a Large Health Care System From 1997 to 2020: A Target Trial Emulation Study.
     Neurology. 2025;105:e213855.
     PubMed     Abstract available
     
     
     
102. GOGNIAT MA, Khan OA, Ratangee B, Bolton CJ, et al
     Cross-Sectional and Longitudinal Associations of Neighborhood Disadvantage With Fluid Biomarkers of Neuroinflammation and Neurodegeneration.
     Neurology. 2025;105:e213770.
     PubMed     Abstract available
     
     
     
103. SELMA-GONZALEZ J, Rubio-Guerra S, Garcia-Castro J, Vera-Campuzano E, et al
     Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease Stages.
     Neurology. 2025;105:e213769.
     PubMed     Abstract available
     
     
     June 2025
104. DUBBELMAN MA, Liu A, Donohue MC, Langford O, et al
     Changes in Daily Functioning in Association With Tau and Amyloid Among Unimpaired Older Adults With and Without Elevated Amyloid.
     Neurology. 2025;104:e213775.
     PubMed     Abstract available
     
     
     
105. CHARISIS S, Lu S, Melgarejo JD, Satizabal CL, et al
     Association of Blood Lipoprotein Levels With Incident Alzheimer Disease in Community-Dwelling Individuals: The Framingham Heart Study.
     Neurology. 2025;104:e213715.
     PubMed     Abstract available
     
     
     
106. SHRESTHA S, Zhu X, Griswold ME, Palta P, et al
     Olfaction and Plasma Biomarkers of Alzheimer Disease and Neurodegeneration in the Atherosclerosis Risk in Communities Study.
     Neurology. 2025;104:e213706.
     PubMed     Abstract available
     
     
     
107. GONZALEZ-ORTIZ F, Kirsebom BE, Yakoub Y, Gundersen JK, et al
     Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer Disease.
     Neurology. 2025;104:e213676.
     PubMed     Abstract available
     
     
     
108. MENDES AJ, Ribaldi F, Pievani M, Boccalini C, et al
     Validating the Amyloid Cascade Through the Revised Criteria of Alzheimer's Association Workgroup 2024 for Alzheimer Disease.
     Neurology. 2025;104:e213675.
     PubMed     Abstract available
     
     
     May 2025
109. LEE JY, Han K, Kim J, Lim JS, et al
     Association Between Metabolic Syndrome and Young-Onset Dementia: A Nationwide Population-Based Study.
     Neurology. 2025;104:e213599.
     PubMed     Abstract available
     
     
     
110. BADER I, Groot C, Van Der Flier WM, Pijnenburg YAL, et al
     Survival Differences Between Individuals With Typical and Atypical Phenotypes of Alzheimer Disease.
     Neurology. 2025;104:e213603.
     PubMed     Abstract available
     
     
     
111. JUSTO AFO, Paradela R, Gomes Goncalves N, Ribeiro Paes V, et al
     Association Between Alcohol Consumption, Cognitive Abilities, and Neuropathologic Changes: A Population-Based Autopsy Study.
     Neurology. 2025;104:e213555.
     PubMed     Abstract available
     
     
     
112. COLLIJ LE, Mastenbroek SE
     Your Alzheimer Risk: How Your Sex and Your Affected Parent's Sex Independently Shape the Odds.
     Neurology. 2025;104:e213622.
     PubMed    
     
     
     
113. OURRY V, Fajardo-Valdez A, Soucy JP, Poirier J, et al
     Amyloid and Tau Pathology in Cognitively Unimpaired Individuals With a Parental History of Alzheimer Disease: Role of Sex and Parent's Sex.
     Neurology. 2025;104:e213507.
     PubMed     Abstract available
     
     
     
114. THOMAS KR, Edmonds EC
     Objective Criteria for Subtle Cognitive Decline in Aging and Preclinical Alzheimer Disease: A Systematic Review.
     Neurology. 2025;104:e213536.
     PubMed     Abstract available
     
     
     
115. STOCKER H, Beyer L, Trares K, Stevenson-Hoare J, et al
     Association of Nonmodifiable Risk Factors With Alzheimer Disease Blood Biomarkers in Community-Dwelling Adults in the ESTHER Study.
     Neurology. 2025;104:e213500.
     PubMed     Abstract available
     
     
     April 2025
116. JEONG SY, Suh CH, Lim JS, Shim WH, et al
     Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-beta Immunotherapy: An Updated Meta-Analysis.
     Neurology. 2025;104:e213483.
     PubMed     Abstract available
     
     
     
117. SHUMAN PARETSKY M
     The Impact of Social Vulnerability on Cognitive Decline and Incident Alzheimer Disease.
     Neurology. 2025;104:e213582.
     PubMed    
     
     
     
118. DESAI P, Bond J, Dhana A, Ng TKS, et al
     The Social Vulnerability Index and Incidence of Alzheimer Disease in a Population-Based Sample of Older Adults.
     Neurology. 2025;104:e213464.
     PubMed     Abstract available
     
     
     
119. NALLAPU BT, Petersen KK, Qian T, Demirsoy I, et al
     A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials.
     Neurology. 2025;104:e213490.
     PubMed     Abstract available
     
     
     
120. PALPATZIS E, Akinci M, Garcia-Prat M, Blennow K, et al
     Grief and Economic Stressors by Sex, Gender, and Education: Associations With Alzheimer Disease-Related Outcomes.
     Neurology. 2025;104:e213377.
     PubMed     Abstract available
     
     
     
121. WILLIAMS JP, Babulal GM
     Hakuna Matata: How Interventions for Stressful Life Events and Other Social Determinants of Health Intersect With Alzheimer Disease.
     Neurology. 2025;104:e213455.
     PubMed    
     
     
     
122. SANCHEZ E, Coughlan GT, Wilkinson T, Ramirez J, et al
     Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases.
     Neurology. 2025;104:e213438.
     PubMed     Abstract available
     
     
     March 2025
123. HOLPER S, Loveland PM, Churilov L, Italiano D, et al
     Author Response: Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis.
     Neurology. 2025;104:e209918.
     PubMed    
     
     
     
124. SIEGLER JE, Galetta SL
     Editors' Note: Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis.
     Neurology. 2025;104:e213477.
     PubMed    
     
     
     
125. JIAO X, Liu X, Tian G
     Reader Response: Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis.
     Neurology. 2025;104:e209897.
     PubMed    
     
     
     
126. CAI W, Neitzel J, Glodzik L, Blacker D, et al
     Effect Modifiers of the Association of Blood Pressure With Brain Amyloid and Tau Pathology.
     Neurology. 2025;104:e213441.
     PubMed     Abstract available
     
     
     
127. TURPIN AL, Felisatti F, Chauveau L, Haudry S, et al
     Association Between Lifestyle at Different Life Periods and Brain Integrity in Older Adults.
     Neurology. 2025;104:e213347.
     PubMed     Abstract available
     
     
     
128. DE GEUS MB, Wu CY, Dodge H, Leslie SN, et al
     Unbiased CSF Proteomics in Patients With Idiopathic Normal Pressure Hydrocephalus to Identify Molecular Signatures and Candidate Biomarkers.
     Neurology. 2025;104:e213375.
     PubMed     Abstract available
     
     
     February 2025
129. LIANG J, Hussainy S, Lee SM, Wu G, et al
     Association of Polygenic Risk Score for 5 Diseases With Alzheimer Disease Progression, Biomarkers, and Amyloid Deposition.
     Neurology. 2025;104:e210250.
     PubMed     Abstract available
     
     
     
130. DARK HE, Shafer AT, Cordon J, An Y, et al
     Association of Plasma Biomarkers of Alzheimer Disease and Neurodegeneration With Longitudinal Intra-Network Functional Brain Connectivity.
     Neurology. 2025;104:e210271.
     PubMed     Abstract available
     
     
     
131. BORNHORST JA, Lundgreen CS, Weigand SD, Figdore DJ, et al
     Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations.
     Neurology. 2025;104:e210287.
     PubMed     Abstract available
     
     
     January 2025
132. QUISPIALAYA KM, Therriault J, Aliaga A, Benedet AL, et al
     Comparison of Plasma p-tau217 and [(18)F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia.
     Neurology. 2025;104:e210211.
     PubMed     Abstract available
     
     
     
133. MOROTTI A, Pilotto A, Zanola D, Galli A, et al
     Cerebral Amyloid Angiopathy in Alzheimer Disease: A Comparison Between Different Versions of the Boston Criteria.
     Neurology. 2025;104:e210248.
     PubMed     Abstract available
     
     
     
134. RODRIGUEZ-BAZ I, Benejam B, Morcillo-Nieto AO, Vaque-Alcazar L, et al
     Posterior Cortical Atrophy Due to Alzheimer Disease in a Person With Down Syndrome: A Case Report.
     Neurology. 2025;104:e210179.
     PubMed     Abstract available
     
     
     
135. GRILL JD, Tam S, Thai G, Vides B, et al
     Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease.
     Neurology. 2025;104:e210152.
     PubMed     Abstract available
     
     
     
136. LEE S, Rajmohan R, Al-Darsani Z, Paganini-Hill A, et al
     Medical Histories Associated With Absence of Alzheimer Disease Neuropathologic Changes in the Oldest-Old: The 90+ Study.
     Neurology. 2025;104:e210107.
     PubMed     Abstract available
     
     
     
137. 
     Association of Seizure Foci and Location of Tau and Amyloid Deposition and Brain Atrophy in Patients With Alzheimer Disease and Seizures.
     Neurology. 2025;104:e210173.
     PubMed    
     
     
     December 2024
138. BOCCALINI C, Dodich A, Scheffler M, Lagana V, et al
     In Vivo Tau and Neurodegeneration Imaging in a Family With the Presenilin 1 Met146Leu Pathogenic Variant.
     Neurology. 2024;103:e210103.
     PubMed     Abstract available
     
     
     
139. 
     Challenges in a Biological Definition of Alzheimer Disease.
     Neurology. 2024;103:e210200.
     PubMed    
     
     
     
140. BISCHOF GN, Jaeger E, Giehl K, Jessen F, et al
     Cortical Tau Aggregation Patterns Associated With Apraxia in Patients With Alzheimer Disease.
     Neurology. 2024;103:e210062.
     PubMed     Abstract available
     
     
     
141. SAFRANSKY M, Groh JR, Blennow K, Zetterberg H, et al
     Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease.
     Neurology. 2024;103:e209866.
     PubMed     Abstract available
     
     
     November 2024
142. SIN MK, Cheng Y, Ahmed A, Roseman JM, et al
     Cerebral Amyloid Angiopathy, Dementia, and Alzheimer Neuropathologic Changes: Findings From the ACT Autopsy Cohort.
     Neurology. 2024;103:e210009.
     PubMed     Abstract available
     
     
     
143. GUSOVSKY AV, Lin CC, Kerber K, Reynolds EL, et al
     Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications.
     Neurology. 2024;103:e210029.
     PubMed     Abstract available
     
     
     
144. LAM AD, Thibault EG, Mayblyum DV, Hsieh S, et al
     Association of Seizure Foci and Location of Tau and Amyloid Deposition and Brain Atrophy in Patients With Alzheimer Disease and Seizures.
     Neurology. 2024;103:e209920.
     PubMed     Abstract available
     
     
     
145. HAZAN J, Liu KY, Costello H, Isaacs JD, et al
     Challenges in a Biological Definition of Alzheimer Disease.
     Neurology. 2024;103:e209884.
     PubMed     Abstract available
     
     
     
146. JAGUST WJ
     Alzheimer Disease Is a Specific Disorder Defined by Neuropathology Detectable During Life.
     Neurology. 2024;103:e209995.
     PubMed    
     
     
     
147. AAMODT WW, Sun C, Dahodwala N, Elser H, et al
     End-of-Life Health Care Service Use and Cost Among Medicare Decedents With Neurodegenerative Diseases.
     Neurology. 2024;103:e209925.
     PubMed     Abstract available
     
     
     October 2024
148. 
     Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome.
     Neurology. 2024;103:e209935.
     PubMed    
     
     
     
149. WANG YY, Wang YJ, Zeng F
     Case of Autosomal-Dominant Alzheimer Disease With Ribbon-Like Cortical Calcifications.
     Neurology. 2024;103:e209860.
     PubMed    
     
     
     
150. LORENZINI L, Maranzano A, Ingala S, Collij LE, et al
     Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia.
     Neurology. 2024;103:e209801.
     PubMed     Abstract available
     
     
     
151. CHARIDIMOU A, Boulouis G
     Core CSF Biomarker Profile in Cerebral Amyloid Angiopathy: Updated Meta-Analysis.
     Neurology. 2024;103:e209795.
     PubMed     Abstract available
     
     
     
152. SON HJ, Kim JS, Bateman RJ, Kim S, et al
     Association of Resilience-Related Life Experiences on Variability on Age of Onset in Dominantly Inherited Alzheimer Disease.
     Neurology. 2024;103:e209766.
     PubMed     Abstract available
     
     
     September 2024
153. ANASTASSIADIS C, Martinez-Valbuena I, Vasilevskaya A, Thapa S, et al
     CSF alpha-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders.
     Neurology. 2024;103:e209818.
     PubMed     Abstract available
     
     
     
154. NEVES BRIARD J, Duquette A, Cayrol R, Lapalme-Remis S, et al
     Refractory Status Epilepticus in a Patient With Aducanumab-Induced Amyloid-Related Imaging Abnormalities.
     Neurology. 2024;103:e209582.
     PubMed     Abstract available
     
     
     
155. LENNON MJ, Lipnicki DM, Lam BCP, Crawford JD, et al
     Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis.
     Neurology. 2024;103:e209715.
     PubMed     Abstract available
     
     
     
156. VILLAIN N, Paretsky MS
     The Great Debate in Diagnosing Alzheimer Disease: More Than Just a beta Test.
     Neurology. 2024;103:e209836.
     PubMed    
     
     
     
157. BIEGER A, Brum WS, Borelli WV, Therriault J, et al
     Influence of Different Diagnostic Criteria on Alzheimer Disease Clinical Research.
     Neurology. 2024;103:e209753.
     PubMed     Abstract available
     
     
     August 2024
158. KRUGER J, Aaltonen M, Aho K, Heikkinen S, et al
     Incidence and Prevalence of Early-Onset Dementia in Finland.
     Neurology. 2024;103:e209654.
     PubMed     Abstract available
     
     
     
159. INGRAM RU, Ocal D, Halai A, Pobric G, et al
     Graded Multidimensional Clinical and Radiologic Variation in Patients With Alzheimer Disease and Posterior Cortical Atrophy.
     Neurology. 2024;103:e209679.
     PubMed     Abstract available
     
     
     
160. ZSADANYI SE, Morcillo-Nieto AO, Aranha MR, Aragon I, et al
     Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome.
     Neurology. 2024;103:e209676.
     PubMed     Abstract available
     
     
     
161. GANESH A, Galetta SL
     Editors' Note: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2024;103:e209634.
     PubMed    
     
     
     
162. CONNOLLY E, O'Connor A, Fallon A, O'Dowd S, et al
     Reader Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2024;103:e209343.
     PubMed    
     
     
     
163. VASSILAKI M, Graff-Radford J
     Author Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2024;103:e209371.
     PubMed    
     
     
     
164. HOLPER S, Loveland P, Churilov L, Italiano D, et al
     Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis.
     Neurology. 2024;103:e209537.
     PubMed     Abstract available
     
     
     July 2024
165. HAMILTON CA, Donaghy PC, Durcan R, Ciafone J, et al
     Outcomes of Patients With Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease at 3 and 5 Years After Diagnosis.
     Neurology. 2024;103:e209499.
     PubMed     Abstract available
     
     
     
166. XIA Y, Dore V, Fripp J, Bourgeat P, et al
     Association of Basal Forebrain Atrophy With Cognitive Decline in Early Alzheimer Disease.
     Neurology. 2024;103:e209626.
     PubMed     Abstract available
     
     
     
167. MASTENBROEK SE, Sala A, Vallez Garcia D, Shekari M, et al
     Continuous beta-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity.
     Neurology. 2024;103:e209419.
     PubMed     Abstract available
     
     
     June 2024
168. DUBINSKY RM, Stein AC
     Predicting Driving Cessation in Alzheimer Disease: Performance Beats Biomarkers.
     Neurology. 2024;102:e209523.
     PubMed    
     
     
     
169. BABULAL GM, Chen L, Murphy SA, Carr DB, et al
     Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments.
     Neurology. 2024;102:e209426.
     PubMed     Abstract available
     
     
     
170. YE R, Goodheart AE, Locascio JJ, Peterec E, et al
     Differential Vulnerability of Hippocampal Subfields to Amyloid and Tau Deposition in the Lewy Body Diseases.
     Neurology. 2024;102:e209460.
     PubMed     Abstract available
     
     
     
171. JADICK MF, Robinson T, Farrell ME, Klinger H, et al
     Associations Between Self and Study Partner Report of Cognitive Decline With Regional Tau in a Multicohort Study.
     Neurology. 2024;102:e209447.
     PubMed     Abstract available
     
     
     
172. SUN M, He Q, Sun N, Han Q, et al
     Intrinsic Capacity, Polygenic Risk Score, APOE Genotype, and Risk of Dementia: A Prospective Cohort Study Based on the UK Biobank.
     Neurology. 2024;102:e209452.
     PubMed     Abstract available
     
     
     
173. BOLSEWIG K, van Unnik AAJM, Blujdea ER, Gonzalez MC, et al
     Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
     Neurology. 2024;102:e209418.
     PubMed     Abstract available
     
     
     May 2024
174. DITTRICH A, Westman E, Shams S, Skillback T, et al
     Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation: The Gothenburg H70 Birth Cohort Study.
     Neurology. 2024;102:e209402.
     PubMed     Abstract available
     
     
     
175. VASSILAKI M, Pittock RR, Aakre JA, Castillo AM, et al
     Author Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2024;102:e209377.
     PubMed    
     
     
     
176. CHIABOTTI PS, Rouaud O, Allali G
     Reader Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2024;102:e209375.
     PubMed    
     
     
     
177. LEWIS A, Galetta S
     Editors' Note: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2024;102:e209376.
     PubMed    
     
     
     
178. WOOD ALEXANDER M, Wu CY, Coughlan GT, Puri T, et al
     Associations Between Age at Menopause, Vascular Risk, and 3-Year Cognitive Change in the Canadian Longitudinal Study on Aging.
     Neurology. 2024;102:e209298.
     PubMed     Abstract available
     
     
     
179. GRASSET L, Bouteloup V, Cacciamani F, Pellegrin I, et al
     Associations Between Blood-Based Biomarkers and Cognitive and Functional Trajectories Among Participants of the MEMENTO Cohort.
     Neurology. 2024;102:e209307.
     PubMed     Abstract available
     
     
     April 2024
180. BUCKLEY RF, Schindler SE
     Lower Accuracy Alzheimer Disease Blood Tests Will Never Be "Ready for Prime Time".
     Neurology. 2024;102:e209295.
     PubMed    
     
     
     
181. BOUTELOUP V, Pellegrin I, Dubois B, Chene G, et al
     Explaining the Variability of Alzheimer Disease Fluid Biomarker Concentrations in Memory Clinic Patients Without Dementia.
     Neurology. 2024;102:e209219.
     PubMed     Abstract available
     
     
     
182. RAJAN KB, Mcaninch EA, Wilson RS, Dhana A, et al
     Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults.
     Neurology. 2024;102:e209168.
     PubMed     Abstract available
     
     
     
183. ASKEN BM, Tanner JA, Vandevrede L, Apple A, et al
     Linking Type and Extent of Head Trauma to Cavum Septum Pellucidum in Older Adults With and Without Alzheimer Disease and Related Dementias.
     Neurology. 2024;102:e209183.
     PubMed     Abstract available
     
     
     
184. NELSON SE, Lopez OL
     Lecanemab for Alzheimer Disease: Is It Worth It?
     Neurology. 2024;102:e209265.
     PubMed    
     
     
     
185. NADEAU SE
     Lecanemab Questions.
     Neurology. 2024;102:e209320.
     PubMed     Abstract available
     
     
     
186. NGUYEN HV, Mital S, Knopman DS, Alexander GC, et al
     Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease.
     Neurology. 2024;102:e209218.
     PubMed     Abstract available
     
     
     
187. ALOSCO ML, Tartaglia MC
     Repetitive Blast Injury and CSF Alzheimer Disease Biomarkers: Navigating a Complex Narrative.
     Neurology. 2024;102:e209294.
     PubMed    
     
     
     
188. LI G, Iliff J, Shofer J, Mayer CL, et al
     CSF beta-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury.
     Neurology. 2024;102:e209197.
     PubMed     Abstract available
     
     
     
189. OVEISGHARAN S, Grodstein F, Evia AM Jr, James BD, et al
     Association of Age-Related Neuropathologic Findings at Autopsy With a Claims-Based Epilepsy Diagnosis in Older Adults.
     Neurology. 2024;102:e209172.
     PubMed     Abstract available
     
     
     
190. WEINSTEIN G, Kojis DJ, Ghosh S, Beiser AS, et al
     Association of Neurotrophic Factors at Midlife With In Vivo Measures of beta-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults.
     Neurology. 2024;102:e209198.
     PubMed     Abstract available
     
     
     
191. LU Y, Pike JR, Hoogeveen R, Walker K, et al
     Nonalcoholic Fatty Liver Disease and Longitudinal Change in Imaging and Plasma Biomarkers of Alzheimer Disease and Vascular Pathology.
     Neurology. 2024;102:e209203.
     PubMed     Abstract available
     
     
     
192. BUCHMAN AS, Yu L, Klein HU, Zammit AR, et al
     Glycoproteome-Wide Discovery of Cortical Glycoproteins That May Provide Cognitive Resilience in Older Adults.
     Neurology. 2024;102:e209223.
     PubMed     Abstract available
     
     
     
193. CAI Y, Shi D, Lan G, Chen L, et al
     Association of beta-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia.
     Neurology. 2024;102:e209205.
     PubMed     Abstract available
     
     
     
194. SCHELTENS P, Atri A, Feldman H, Hansson O, et al
     Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer's Disease (P11-9.013).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
195. HENEKA M, Gauthier S, Chandekar SA, Hahn-Pedersen JH, et al
     The Role of Neuroinflammation in Alzheimer's Disease: A Systematic Literature Review (P7-9.013).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
196. GREENBERG S, Battioui C, Lu M, Biffi A, et al
     ARIA Insights from the Donanemab Trials (P1-9.001).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
197. BERTON G, Moreira M, Rodrigues ACLF, Donadon IB, et al
     Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Sleep Deprived Patients: A Systematic Review and Meta-analysis (P8-9.008).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
198. APPLETON J, Funk Q, Fregonara PZ, Yu M, et al
     Neuroinflammation Co-localizes Highly with Tau in Mild Cognitive Impairment from Early Onset Alzheimer's Disease (N4.002).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
199. SAHAY S, Imami A, Hamoud A, McCullumsmith R, et al
     Towards Timely Alzheimer's Diagnosis: A Clinical Data-Driven Approach to Biomarker Discovery (P7-9.016).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     March 2024
200. HONIG M, Altomare D, Caprioglio C, Collij L, et al
     Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease.
     Neurology. 2024;102:e208053.
     PubMed     Abstract available
     
     
     
201. ACKLEY S, Calmasini C, Bouteloup V, Hill-Jarrett TG, et al
     Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort.
     Neurology. 2024;102:e208054.
     PubMed     Abstract available
     
     
     
202. GUO C, Harshfield EL, Markus HS
     Sleep Characteristics and Risk of Stroke and Dementia: An Observational and Mendelian Randomization Study.
     Neurology. 2024;102:e209141.
     PubMed     Abstract available
     
     
     
203. FLEISHER AS, Munsie LM, Perahia DGS, Andersen SW, et al
     Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
     Neurology. 2024;102:e208061.
     PubMed     Abstract available
     
     
     
204. CHRISTENSEN GM, Li Z, Liang D, Ebelt S, et al
     Association of PM(2.5) Exposure and Alzheimer Disease Pathology in Brain Bank Donors-Effect Modification by APOE Genotype.
     Neurology. 2024;102:e209162.
     PubMed     Abstract available
     
     
     February 2024
205. HILL-JARRETT TG, Choi M, Buto PT, Miramontes S, et al
     Associations of Everyday and Lifetime Experiences of Discrimination With Willingness to Undergo Alzheimer Disease Predictive Testing.
     Neurology. 2024;102:e208005.
     PubMed     Abstract available
     
     
     
206. PASE MP, Himali JJ, Puerta R, Beiser AS, et al
     Association of Plasma YKL-40 With MRI, CSF, and Cognitive Markers of Brain Health and Dementia.
     Neurology. 2024;102:e208075.
     PubMed     Abstract available
     
     
     
207. YASAR S, Nidadavolu L
     Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention.
     Neurology. 2024;102:e209180.
     PubMed    
     
     
     
208. ADESUYAN M, Jani YH, Alsugeir D, Howard R, et al
     Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study.
     Neurology. 2024;102:e209131.
     PubMed     Abstract available
     
     
     
209. SHINOTOH H
     White Matter Neuroinflammation Matters in Early Alzheimer Disease.
     Neurology. 2024;102:e208090.
     PubMed    
     
     
     
210. TARAWNEH R
     YKL-40 as a New Plasma Biomarker for Dementia Risk: Are We There Yet?
     Neurology. 2024;102:e209145.
     PubMed    
     
     
     
211. HARDY J, Schott JM
     Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities.
     Neurology. 2024;102:e208096.
     PubMed     Abstract available
     
     
     
212. LOOMIS SJ, Miller R, Castrillo-Viguera C, Umans K, et al
     Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.
     Neurology. 2024;102:e207919.
     PubMed     Abstract available
     
     
     
213. CHOLERTON B, Latimer CS, Crane PK, Corrada MM, et al
     Neuropathologic Burden and Dementia in Nonagenarians and Centenarians.
     Neurology. 2024;102:e208060.
     PubMed     Abstract available
     
     
     
214. PARK SY, Setiawan VW, Crimmins EM, White LR, et al
     Racial and Ethnic Differences in the Population-Attributable Fractions of Alzheimer Disease and Related Dementias.
     Neurology. 2024;102:e208116.
     PubMed     Abstract available
     
     
     
215. WANG Q, Schindler SE, Chen G, Mckay NS, et al
     Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging.
     Neurology. 2024;102:e208013.
     PubMed     Abstract available
     
     
     
216. COUSINS KAQ, Irwin DJ, Tropea TF, Rhodes E, et al
     Evaluation of ATN(PD) Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
     Neurology. 2024;102:e208033.
     PubMed     Abstract available
     
     
     January 2024
217. CASTILHOS RM, Snitz BE
     Longitudinal Cognitive Decline in Alzheimer Disease Prevention Trials.
     Neurology. 2024;102:e208067.
     PubMed     Abstract available
     
     
     
218. DUBBELMAN MA, Hendriksen HMA, Harrison JE, Vijverberg EGB, et al
     Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups.
     Neurology. 2024;102:e207978.
     PubMed     Abstract available
     
     
     
219. LOPEZ OL, Villemagne VL, Chang YF, Cohen AD, et al
     Association Between beta-Amyloid Accumulation and Incident Dementia in Individuals 80 Years or Older Without Dementia.
     Neurology. 2024;102:e207920.
     PubMed     Abstract available
     
     
     
220. PEROSA V, Zanon Zotin MC, Schoemaker D, Sveikata L, et al
     Association Between Hippocampal Volumes and Cognition in Cerebral Amyloid Angiopathy.
     Neurology. 2024;102:e207854.
     PubMed     Abstract available
     
     
     
221. ZANON ZOTIN MC, Makkinejad N, Schneider JA, Arfanakis K, et al
     Sensitivity and Specificity of the Boston Criteria Version 2.0 for the Diagnosis of Cerebral Amyloid Angiopathy in a Community-Based Sample.
     Neurology. 2024;102:e207940.
     PubMed     Abstract available
     
     
     December 2023
222. HANSEEUW BJ, Jacobs HIL, Schultz AP, Buckley RF, et al
     Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults.
     Neurology. 2023;101:e2533-e2544.
     PubMed     Abstract available
     
     
     November 2023
223. ZHOU Z, Ryan J, Tonkin AM, Zoungas S, et al
     Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults: A Prospective Cohort Study.
     Neurology. 2023;101:e2288-e2299.
     PubMed     Abstract available
     
     
     
224. YOON SH, Kim HK, Lee JH, Chun JH, et al
     Association of Sleep Disturbances With Brain Amyloid and Tau Burden, Cortical Atrophy, and Cognitive Dysfunction Across the AD Continuum.
     Neurology. 2023;101:e2162-e2171.
     PubMed     Abstract available
     
     
     
225. FERGUSON EL, Zimmerman SC, Jiang C, Choi M, et al
     Low- and High-Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members of a Large Health Care Plan.
     Neurology. 2023;101:e2172-e2184.
     PubMed     Abstract available
     
     
     
226. NELSON PT, Jicha GA
     Early Hippocampal Atrophy Is an Important Signal for Clinicians, but Not Necessarily a Harbinger of Alzheimer Disease.
     Neurology. 2023 Nov 15:10.1212/WNL.0000000000208071.
     PubMed    
     
     
     
227. PITTOCK RR, Aakre JA, Castillo AM, Ramanan VK, et al
     Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2023;101:e1837-e1849.
     PubMed     Abstract available
     
     
     
228. HOWE MD, Rabinovici GD, Salloway SP
     Real-World Application of Anti-beta-Amyloid Monoclonal Antibodies: Untangling Eligibility.
     Neurology. 2023;101:811-812.
     PubMed    
     
     
     October 2023
229. THEIS H, Bischof GN, Bruggemann N, Dargvainiene J, et al
     In Vivo Measurement of Tau Depositions in Anti-IgLON5 Disease Using (18)F-PI-2620 PET.
     Neurology. 2023 Oct 25:10.1212/WNL.0000000000207870.
     PubMed     Abstract available
     
     
     
230. ALAM JJ, Maruff P, Doctrow SR, Chu HM, et al
     Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.
     Neurology. 2023;101:e1708-e1717.
     PubMed     Abstract available
     
     
     
231. SANTAMARIA BA, Corroza J, Sanchez-Ruiz de Gordoa J, Cabello C, et al
     Association of Blood-Based DNA Methylation Markers With Late-Onset Alzheimer Disease: A Potential Diagnostic Approach.
     Neurology. 2023 Oct 12:10.1212/WNL.0000000000207865.
     PubMed     Abstract available
     
     
     
232. STARK M, Wolfsgruber S, Kleineidam L, Frommann I, et al
     Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline.
     Neurology. 2023 Oct 11:10.1212/WNL.0000000000207844.
     PubMed     Abstract available
     
     
     
233. GONZALES MM, Vela G, Philip V, Trevino H, et al
     Demographic and Clinical Characteristics Associated With Serum GFAP Levels in an Ethnically Diverse Cohort.
     Neurology. 2023;101:e1531-e1541.
     PubMed     Abstract available
     
     
     
234. OVEISGHARAN S, Yu L, Agrawal S, Nag S, et al
     Relation of Motor Impairments to Neuropathologic Changes of Limbic-Predominant Age-Related TDP-43 Encephalopathy in Older Adults.
     Neurology. 2023;101:e1542-e1553.
     PubMed     Abstract available
     
     
     
235. BONOMI S, Samara A, Balestra N, Padalia A, et al
     Teaching NeuroImage: Severe Amyloid-Related Imaging Abnormalities After Anti-beta-Amyloid Monoclonal Antibody Treatment.
     Neurology. 2023 Oct 10:10.1212/WNL.0000000000207927.
     PubMed    
     
     
     
236. BRENNER S
     Reader Response: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
     Neurology. 2023;101:633-634.
     PubMed    
     
     
     
237. OVEISGHARAN S, Bennett DA
     Author Response: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
     Neurology. 2023;101:634.
     PubMed    
     
     
     
238. GANESH A, Galetta S
     Editors' Note: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
     Neurology. 2023;101:633.
     PubMed    
     
     
     
239. LEWIS A, Gupta A, Oh I, Schindler SE, et al
     Association Between Socioeconomic Factors, Race, and Use of a Specialty Memory Clinic.
     Neurology. 2023;101:e1424-e1433.
     PubMed     Abstract available
     
     
     September 2023
240. GOODSMITH MS, Wroblewski KE, Schumm LP, McClintock MK, et al
     Association of APOE epsilon4 Status With Long-term Declines in Odor Sensitivity, Odor Identification, and Cognition in Older US Adults.
     Neurology. 2023;101:e1341-e1350.
     PubMed     Abstract available
     
     
     
241. COOMANS EM, de Koning LA, Rikken RM, Verfaillie SC, et al
     Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies.
     Neurology. 2023 Sep 25:10.1212/WNL.0000000000207794.
     PubMed     Abstract available
     
     
     
242. MALPETTI M, Rabinovici GD
     From Clinical Trials to Memory Clinics, tau-PET Visual Reads Can Help Diagnosis and Patient Stratification.
     Neurology. 2023 Sep 25:10.1212/WNL.0000000000207935.
     PubMed    
     
     
     
243. YAMAGUCHI S, Murakami T, Satoh M, Komiyama T, et al
     Associations of Dental Health With the Progression of Hippocampal Atrophy in Community-Dwelling Individuals: The Ohasama Study.
     Neurology. 2023;101:e1056-e1068.
     PubMed     Abstract available
     
     
     August 2023
244. MONTEIRO C, Toth B, Brunstein F, Bobbala A, et al
     A Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants with Mild-to-Moderate Alzheimer's Disease (Lauriet).
     Neurology. 2023 Aug 29:10.1212/WNL.0000000000207663.
     PubMed     Abstract available
     
     
     
245. EDLAND SD, Ucsd, Llibre-Guerra JJ
     Semorinemab in Mild to Moderate Alzheimer Disease: A Glimmer of Hope Though Cautions Remain.
     Neurology. 2023 Aug 29:10.1212/WNL.0000000000207861.
     PubMed    
     
     
     
246. KAMAL F, Morrison C, Maranzano J, Zeighami Y, et al
     White Matter Hyperintensity Trajectories in Patients With Progressive and Stable Mild Cognitive Impairment.
     Neurology. 2023;101:e815-e824.
     PubMed     Abstract available
     
     
     
247. PARNETTI L, Bellomo G
     Advances in Diagnosis and Prognosis of Parkinson Disease: Value of Cerebrospinal Fluid Proteomics.
     Neurology. 2023 Aug 16:10.1212/WNL.0000000000207724.
     PubMed    
     
     
     
248. KAWADA T
     Reader Response: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
     Neurology. 2023;101:333-334.
     PubMed    
     
     
     
249. PROSSER L
     Author Response: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
     Neurology. 2023;101:334.
     PubMed    
     
     
     
250. LEWIS A, Galetta S
     Editors' Note: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
     Neurology. 2023;101:333.
     PubMed    
     
     
     
251. RAMANAN VK, Graff-Radford J, Syrjanen J, Shir D, et al
     Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort.
     Neurology. 2023 Aug 14:10.1212/WNL.0000000000207675.
     PubMed     Abstract available
     
     
     
252. CATHARINA BOON BD, Labuzan S, Peng Z, Matchett B, et al
     Retrospective Evaluation of Neuropathologic Proxies of the Minimal Atrophy Subtype Compared to Corticolimbic Alzheimer Disease Subtypes.
     Neurology. 2023 Aug 14:10.1212/WNL.0000000000207685.
     PubMed     Abstract available
     
     
     
253. LAM AD
     Linking Late-Onset Epilepsy With Alzheimer Disease: Insights From Plasma Amyloid Measurements.
     Neurology. 2023 Aug 4:10.1212/WNL.0000000000207683.
     PubMed    
     
     
     
254. JOHNSON EL, Sullivan KJ, Schneider ALC, Simino J, et al
     Association of Plasma Abeta 42/40 Ratio and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study.
     Neurology. 2023 Aug 4:10.1212/WNL.0000000000207635.
     PubMed     Abstract available
     
     
     
255. HADDAD A, Brunel G, Indart S, Paquet C, et al
     A Patient With the Posterior Variant of Alzheimer Disease Plays Table Tennis: Blindsight and Pingpong.
     Neurology. 2023 Aug 3:10.1212/WNL.0000000000207650.
     PubMed    
     
     
     July 2023
256. DURCAN R, Roberts G, Hamilton CA, Donaghy PC, et al
     Serial Nigrostriatal Dopaminergic Imaging in Mild Cognitive Impairment With Lewy Bodies, Alzheimer Disease, and Age-Matched Controls.
     Neurology. 2023 Jul 31:10.1212/WNL.0000000000207621.
     PubMed     Abstract available
     
     
     
257. RAMANAN VK, Armstrong MJ, Choudhury P, Coerver K, et al
     Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology.
     Neurology. 2023 Jul 26:10.1212/WNL.0000000000207757.
     PubMed     Abstract available
     
     
     
258. PROKOPIOU PC, Engels-Dominguez N, Schultz AP, Sepulcre J, et al
     Association of Novelty-Related Locus Coeruleus Function With Entorhinal Tau Deposition and Memory Decline in Preclinical Alzheimer Disease.
     Neurology. 2023 Jul 25:10.1212/WNL.0000000000207646.
     PubMed     Abstract available
     
     
     
259. KARCESKI S, Antonopoulos M
     Biomarkers in Alzheimer Disease: A Review.
     Neurology. 2023;101:e461-e463.
     PubMed    
     
     
     
260. ANDRE C, Kuhn E, Rehel S, Ourry V, et al
     Association of Sleep-Disordered Breathing and Medial Temporal Lobe Atrophy in Cognitively Unimpaired Amyloid-Positive Older Adults.
     Neurology. 2023;101:e370-e385.
     PubMed     Abstract available
     
     
     
261. ALCOLEA D, Beeri MS, Rojas JC, Gardner RC, et al
     Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist.
     Neurology. 2023;101:172-180.
     PubMed     Abstract available
     
     
     
262. BURKE JF, Richard S, Langa KM, Albin RL, et al
     Lecanemab: Looking Before We Leap.
     Neurology. 2023 Jul 21:10.1212/WNL.0000000000207505.
     PubMed     Abstract available
     
     
     
263. SHIR D, Pham NTT, Botha H, Koga S, et al
     Clinicoradiologic and Neuropathologic Evaluation of Corticobasal Syndrome.
     Neurology. 2023;101:e289-e299.
     PubMed     Abstract available
     
     
     
264. DITTRICH A, Ashton NJ, Zetterberg H, Blennow K, et al
     Association of Chronic Kidney Disease With Plasma NfL and Other Biomarkers of Neurodegeneration: The H70 Birth Cohort Study in Gothenburg.
     Neurology. 2023;101:e277-e288.
     PubMed     Abstract available
     
     
     
265. MOSER ED, Manemann SM, Larson NB, St Sauver JL, et al
     Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease Related Dementias.
     Neurology. 2023 Jul 5:10.1212/WNL.0000000000207595.
     PubMed     Abstract available
     
     
     
266. BARBA L, Abu-Rumeileh S, Halbgebauer S, Bellomo G, et al
     CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease.
     Neurology. 2023;101:e50-e62.
     PubMed     Abstract available
     
     
     
267. FERREIRA PCL, Ferrari-Souza JP, Tissot C, Bellaver B, et al
     Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials.
     Neurology. 2023;101:38-45.
     PubMed     Abstract available
     
     
     
268. LICHTER DG, Hershey L
     Proposal to Add FDG-PET as an Outcome Measure for Clinical Trials in Patients With Prodromal Lewy Body Dementia.
     Neurology. 2023 Jul 3:10.1212/WNL.0000000000207498.
     PubMed    
     
     
     June 2023
269. KNOPMAN DS, Hershey L
     Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift.
     Neurology. 2023 Jun 9:10.1212/WNL.0000000000207438.
     PubMed     Abstract available
     
     
     May 2023
270. GROBER E, Petersen KK, Lipton RB, Hassenstab J, et al
     Association of Stages of Objective Memory Impairment With Incident Symptomatic Cognitive Impairment in Cognitively Normal Individuals.
     Neurology. 2023;100:e2279-e2289.
     PubMed     Abstract available
     
     
     
271. FANG Y, Si X, Wang J, Wang Z, et al
     Alzheimer Disease and Epilepsy: A Mendelian Randomization Study.
     Neurology. 2023 May 24:10.1212/WNL.0000000000207423.
     PubMed     Abstract available
     
     
     
272. LUO J, Ma Y, Agboola FJ, Grant E, et al
     Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Lifespan.
     Neurology. 2023 May 18:10.1212/WNL.0000000000207378.
     PubMed     Abstract available
     
     
     
273. DIAZ-GALVAN P, Przybelski SA, Lesnick TG, Schwarz CG, et al
     beta-Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies.
     Neurology. 2023 May 18:10.1212/WNL.0000000000207393.
     PubMed     Abstract available
     
     
     
274. ALVES F, Kalinowski P, Ayton S
     Accelerated Brain Volume Loss Caused by Anti-beta-Amyloid Drugs: A Systematic Review and Meta-analysis.
     Neurology. 2023;100:e2114-e2124.
     PubMed     Abstract available
     
     
     
275. DU J, Li A, Shi D, Chen X, et al
     Association of APOE4, Osteoarthritis, beta-Amyloid, and Tau Accumulation in Primary Motor and Somatosensory Regions in Alzheimer Disease.
     Neurology. 2023 May 15:10.1212/WNL.0000000000207369.
     PubMed     Abstract available
     
     
     
276. BUTLER PAGNOTTI RM, Pudumjee SB, Cross CL, Miller JB, et al
     Cognitive and Clinical Characteristics of Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy.
     Neurology. 2023;100:e2027-e2035.
     PubMed     Abstract available
     
     
     
277. CICOGNOLA C, Mattsson-Carlgren N, van Westen D, Zetterberg H, et al
     Associations of CSF PDGFRbeta With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.
     Neurology. 2023 May 3:10.1212/WNL.0000000000207358.
     PubMed     Abstract available
     
     
     
278. SINHA N, Gugger JJ
     Towards a Patient-Specific Readout of Neurodegeneration: The Case for Spatial Normative Modeling in Alzheimer Disease.
     Neurology. 2023 May 1:10.1212/WNL.0000000000207280.
     PubMed    
     
     
     
279. VERDI S, Kia SM, Yong KXX, Tosun D, et al
     Revealing Individual Neuroanatomical Heterogeneity in Alzheimer Disease Using Neuroanatomical Normative Modeling.
     Neurology. 2023 May 1:10.1212/WNL.0000000000207298.
     PubMed     Abstract available
     
     
     April 2023
280. GERTJE EC, Janelidze S, van Westen D, Cullen N, et al
     Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.
     Neurology. 2023;100:e1812-e1824.
     PubMed     Abstract available
     
     
     
281. KUHN E, Perrotin A, La Joie R, Touron E, et al
     Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum.
     Neurology. 2023 Apr 21:10.1212/WNL.0000000000207338.
     PubMed     Abstract available
     
     
     
282. INSEL PS, Kumar A, Hansson O, Mattsson-Carlgren N, et al
     Genetic Moderation of the Association of beta-Amyloid With Cognition and MRI in Alzheimer Disease.
     Neurology. 2023 Apr 21:10.1212/WNL.0000000000207305.
     PubMed     Abstract available
     
     
     
283. BRUMM MC, Pierz KA, Lafontant DE, Caspell-Garcia C, et al
     Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older.
     Neurology. 2023;100:e1691-e1701.
     PubMed     Abstract available
     
     
     
284. YANG Z, Wei C, Li X, Yuan J, et al
     Association Between Regular Laxative Use and Incident Dementia in UK Biobank Participants.
     Neurology. 2023;100:e1702-e1711.
     PubMed     Abstract available
     
     
     
285. TIAN J, Raghavan Pillai SK, Reid RI, Przybelski SA, et al
     White Matter Degeneration Pathways Associated With Tau Deposition in Alzheimer Disease.
     Neurology. 2023 Apr 17:10.1212/WNL.0000000000207250.
     PubMed     Abstract available
     
     
     
286. BRODTMANN A, Beversdorf DQ
     The Alzheimer Disconnectome.
     Neurology. 2023 Apr 17:10.1212/WNL.0000000000207303.
     PubMed    
     
     
     
287. 
     Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-beta-Amyloid Immunotherapy: A Meta-analysis.
     Neurology. 2023 Apr 4:10.1212/WNL.0000000000207344.
     PubMed    
     
     
     
288. WANG Y, Liang J, Fang Y, Yao D, et al
     Burden of Common Neurologic Diseases in Asian Countries, 1990-2019: An Analysis for the Global Burden of Disease Study 2019.
     Neurology. 2023 Apr 4:10.1212/WNL.0000000000207218.
     PubMed     Abstract available
     
     
     March 2023
289. BARKHOF F, Knopman DS
     Brain Shrinkage in Anti-beta-Amyloid Alzheimer Trials: Neurodegeneration or Pseudo-atrophy?
     Neurology. 2023 Mar 27:10.1212/WNL.0000000000207268.
     PubMed    
     
     
     
290. ZHANG Y, Liu X, Wiggins KL, Kurniansyah N, et al
     Association of Mitochondrial DNA Copy Number With Brain MRI Markers and Cognitive Function: A Meta-analysis of Community-Based Cohorts.
     Neurology. 2023 Mar 16:10.1212/WNL.0000000000207157.
     PubMed     Abstract available
     
     
     
291. AGARWAL P, Leurgans SE, Agrawal S, Aggarwal N, et al
     Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology.
     Neurology. 2023 Mar 8:10.1212/WNL.0000000000207176.
     PubMed     Abstract available
     
     
     
292. KURIHARA M, Komatsu H, Sengoku R, Shibukawa M, et al
     CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease.
     Neurology. 2023;100:e1009-e1019.
     PubMed     Abstract available
     
     
     
293. CHAPMAN S, Renteria MA, Dworkin JD, Garriga SM, et al
     Association of Subjective Cognitive Decline With Progression to Dementia in a Cognitively Unimpaired Multiracial Community Sample.
     Neurology. 2023;100:e1020-e1027.
     PubMed     Abstract available
     
     
     February 2023
294. TIAN Q, An Y, Kitner-Triolo MH, Davatzikos C, et al
     Associations of Olfaction With Longitudinal Trajectories of Brain Volumes and Neuropsychological Function in Older Adults.
     Neurology. 2023;100:e964-e974.
     PubMed     Abstract available
     
     
     
295. SARTO J, Ruiz-Garcia R, Guillen N, Ramos-Campoy O, et al
     Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort.
     Neurology. 2023;100:e860-e873.
     PubMed     Abstract available
     
     
     
296. FERREIRA D, Przybelski SA, Lesnick TG, Schwarz CG, et al
     Cross-sectional Associations of beta-Amyloid, Tau, and Cerebrovascular Biomarkers With Neurodegeneration in Probable Dementia With Lewy Bodies.
     Neurology. 2023;100:e846-e859.
     PubMed     Abstract available
     
     
     December 2022
297. BARRIO IR, Miki Y, Jaunmuktane ZT, Warner T, et al
     Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy.
     Neurology. 2022 Dec 16:10.1212/WNL.0000000000201659.
     PubMed     Abstract available
     
     
     November 2022
298. PROSSER L, MacDougall A, Sudre CH, Manning EN, et al
     Predicting Cognitive Decline in Nondemented Elders Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
     Neurology. 2022 Nov 10. pii: WNL.0000000000201572.
     PubMed     Abstract available
     
     
     October 2022
299. SUCHY-DICEY AM, Oziel K, Sawyer C, Olufadi Y, et al
     Educational and Clinical Associations With Longitudinal Cognitive Function and Brain Imaging in American Indians: The Strong Heart Study.
     Neurology. 2022 Oct 26. pii: WNL.0000000000201261.
     PubMed     Abstract available
     
     
     September 2022
300. ROMERO JR, Pinheiro A, Aparicio HJ, DeCarli CS, et al
     MRI Visible Perivascular Spaces and Risk of Incident Dementia: The Framingham Heart Study.
     Neurology. 2022 Sep 29. pii: WNL.0000000000201293.
     PubMed     Abstract available
     
     
     May 2022
301. TOLLER G, Cobigo Y, Ljubenkov PA, Appleby BS, et al
     Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia.
     Neurology. 2022 May 18. pii: WNL.0000000000200582.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum